Extended indication Maat013 monotherapy for salvage treatment of gastrointestinal Acute graft versus host disease in adults and elderly who are refractory to both steroid
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance MaaT013
Domain Hematology
Reason of inclusion New medicine (specialité)
Main indication Graft versus Host
Extended indication Maat013 monotherapy for salvage treatment of gastrointestinal Acute graft versus host disease in adults and elderly who are refractory to both steroids, the standard of care used as first-line treatment, and to ruxolitinib used as a second-line treatment
Manufacturer Maatpharma
Mechanism of action Unknown
Route of administration Rectal
Therapeutical formulation Unknown
Budgetting framework Intermural (MSZ)
Additional remarks Suspensie voor rectaal gebruik.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date February 2025
Expected Registration March 2026
Orphan drug Yes
Registration phase Clinical trials
Additional remarks Indieningsdatum en verwachte registratie op basis van IHSI-inschatting.

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

References NCT04769895 (ARES)

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information